Cell therapy for idiopathic pulmonary fibrosis (IPF)
Part of Lungs & breathing clinical trials.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 80 years old.
- You must have a confirmed diagnosis of IPF.
- You must be able to walk at least 150 meters (about 2 city blocks) but less than 600 meters (about 6 blocks) in 6 minutes, OR have a breathing test result that is above 30% of the normal predicted value.
- You cannot be pregnant, breastfeeding, or planning pregnancy for at least a year after treatment. Men must not have a partner planning to become pregnant.
- You cannot have active cancer, a recent lung infection, or a recent worsening of IPF (within the last 4 weeks).
- You must not have used any other investigational drugs or biologics in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This trial tests a new immune-based therapy called CAR-DC for people with advanced IPF whose disease is still getting worse despite standard treatments. It aims to slow down or stop the scarring in the lungs, offering a new option for those who are not getting a lung transplant.
This trial tests a new inhaled therapy made from tiny particles derived from placental cells, which may help reduce scarring in the lungs. It is a phase 1 study, so the main goal is to check safety and see if the treatment has any effect on IPF.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This study tests a new medicine called AGMB-447 for people with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes scarred and breathing becomes harder. The goal is to see if the treatment is safe and helps improve lung function.
This trial tests a new medicine called AK3280 to see if it can help people with idiopathic pulmonary fibrosis (a lung disease that causes scarring). It aims to slow down the worsening of lung function. If you have IPF and haven't been treated with anti-fibrotic drugs recently, you might be able to join.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.